CN101422562A - Medicine for treating premature beat and atrial fibrillation - Google Patents
Medicine for treating premature beat and atrial fibrillation Download PDFInfo
- Publication number
- CN101422562A CN101422562A CNA2007101577552A CN200710157755A CN101422562A CN 101422562 A CN101422562 A CN 101422562A CN A2007101577552 A CNA2007101577552 A CN A2007101577552A CN 200710157755 A CN200710157755 A CN 200710157755A CN 101422562 A CN101422562 A CN 101422562A
- Authority
- CN
- China
- Prior art keywords
- radix
- atrial fibrillation
- medicine
- ginseng
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a medicament for treating premature beats and atrial fibrillation, which relates to a Chinese herb, in particular to a medicament for treating premature beats and atrial fibrillation. The medicament is mainly used for treating diseases such as deficiency of both qi and yin, palpitation of blood stasis internal disturbance, shortness of breath, headache, dizziness and hypodynamia, burnout and disinclination to talk, insomnia and dreaminess, lusterless complexion, chest distress and dull pain form time to time, easy excessive tire when working, precordial disstress, rear back pain, tongue slight red or having teeth prints, ecchymosis, weak pulse or intermittent pulse caused by various reasons. The invention provides a medicament which has a determined curative effect, small toxic and side effects, stable and reliable quality and low cost and can treat premature beats and atrial fibrillation. The medicament comprises eight Chinese herbs, such as baked licorice, charles abraham, ginseng, astragalus, tuber of dwarf lilyturf, salvia miltiorrhiza, safflower and wild jujube with the weight ratios as follows: baked licorice: 15to 40g, charles abraham: 20 to 30g, ginseng: 10 to 25g, astragalus: 20 to 40g, tuber of dwarf lilyturf: 20 to 40g, salvia miltiorrhiza: 20 to 40g, safflower: 10 to 25g and wild jujube: 20 to 40g.
Description
Technical field:
A kind of medicine for the treatment of premature beat, atrial fibrillation relates to a kind of Chinese herbal medicine, especially relates to a kind of medicine for the treatment of premature beat, atrial fibrillation; Be mainly used in the deficiency of both QI and YIN, the blood stasis Phlegm-Heat Internal confusion Type cardiopalmus that cause of treatment a variety of causes, breathe hard, have a headache, end when doing when dizzy weak, tiredness with no desire to speak, insomnia and dreamful sleep, lustreless complexion, sensation of oppression and faint pain in the chest, meet labor what for, pareordia discomfort, back part pain, tongue is red partially or indentation, ecchymosis are arranged, thready and weak pulse or knot generation.
Background technology:
Premature beat also claims " premature beat " or " beating before the phase ", is on the basis of hole or ectopic cardiac rhythm, and certain of conducting system of heart is a bit sent excitement ahead of time, causes part or all generation depolarization of heart prematurely.This excitement can be in the atrium, atrioventricular junction (interface) or ventricle, therefore can be called room, atrioventricular junction, premature ventricular beat.Premature beat normally and under the pathologic condition all can take place, but sees so that the latter is more.Atrial fibrillation is called for short atrial fibrillation (AF), is meant that producing per minute in the atrium reaches 350-600 irregular impulsion, and the extremely inharmonic unrest of each several part muscle fiber is quivered in the atrium, thereby has lost effective contraction.The overwhelming majority has betided cardiopathic patient such as rheumatic heart disease, coronary heart disease and hypertension etc., and very high disability rate and fatality rate are arranged.Epidemiology shows: the patients with atrial fibrillation of the U.S. estimates at 2,200,000 examples, in the patients with atrial fibrillation of the annual new diagnosis of Britain more than 4.6 ten thousand examples, the epidemiology situation of China AF is still not abundant, estimate that national AF patient is more than 1,000 ten thousand, up-to-date studies show that, Chinese AF prevalence is 0.77%, and after 50 years old, every increase of age 10 years old, the sickness rate of atrial fibrillation increases by 1 times.Along with socioeconomic change, the variation of people life style, China cardiovascular diseases's morbidity is growing trend.And premature beat, atrial fibrillation and various cardiovascular disease are closely related.Therefore, prevention and treatment premature beat, atrial fibrillation improve people's health level for the quality of life of improving people, and the generation that prevents and treats great cardiovascular and cerebrovascular disease is significant.
Three kinds of situations that all ARR generations form unusual, exciting conduction abnormalities and both and deposit nothing more than excitement.The Western medicine antiarrhythmic drug mainly is divided into four big classes at present: sodium channel inhibitor, beta-blocker, the time-histories agent of over reach current potential and calcium channel blocker, treatment meanss such as catheter ablation art, maze operation, embedded defibrillator are mainly adopted in non-drug therapy.Western medicine is because side effect and drug resistance problem are difficult to reach ideal therapeutic purposes, and operative treatment has only 27% owing to need medicine to keep sinus rhythm behind the restriction of its indication and the conversion for long-term AF conversion.In recent years, the research of Chinese medicine prevention arrhythmia has obtained encouraging success, demonstrates remarkable advantages.The Chinese medicine good effect especially has the efficacy enhancing and toxicity reducing effect with the Western medicine adapted, obviously improves people's quality of life.At present the ARR Chinese patent medicine of treatment mainly contain that step-length WENXIN KELI, Radix Ginseng tablet, LIUWEI DIHUANG WAN (concentrated type), Semen Ziziphi Spinosae ball, TONGMAIYANXINWAN, mind calming health-care capsule, cardiac muscle are logical, GUIPI WAN, mind-easing tonic bolus with arborvitate seed, Tianwang Buxin Dan, BUZHONG YIQI WAN etc., and Chinese medicine oral liquid such as SHENGMAI YIN KOUFUYE are used also more clinically, and have obtained good effect.The traditional Chinese medical science mainly is determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, can get effect at a certain pathogenesis medication, but treatment premature beat, atrial fibrillation be there is no significant curative effect.
Summary of the invention:
The present invention is exactly at the problems referred to above, and a kind of determined curative effect, the treatment premature beat that toxic and side effects is little, steady quality is reliable, cost is low, the medicine of atrial fibrillation are provided.
To achieve these goals, the present invention adopts following technical scheme, the present invention includes Radix Glycyrrhizae Preparata, the Radix Rehmanniae, Radix Ginseng, the Radix Astragali, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Flos Carthami, Semen Ziziphi Spinosae eight flavor Chinese medicines, each constituent content is by weight: Radix Glycyrrhizae Preparata 15-40g, Radix Rehmanniae 20-30g, Radix Ginseng 10-25g, Radix Astragali 20-40g, Radix Ophiopogonis 20-40g, Radix Salviae Miltiorrhizae 20-40g, Flos Carthami 10-25g, Semen Ziziphi Spinosae 20-40g.
The traditional Chinese medical science belongs to premature beat, atrial fibrillation in the categories such as cardiopalmus, palpitation with a distress feeling, short, disease, bird-pecking pulse, thinks the generation of primary disease, stagnates in normal because visceral dysfunction, deficiency of qi and blood, stagnation of QI due to depression of the liver, the phlegm-damp, due to the stagnation of heart-blood.Or be old deficiency of YIN-blood, be difficult to fill arteries and veins, so that the blood vessels operation is unable; Or depressed emotion, stagnated QI transforming into fire, refining liquid is expectorant; Or eating and drinking without temperance, impairing the spleen and stomach, the fortuneization imbalance is wet and is gathered into expectorant, and the heart disturbed by phlegm-fire blocks due to the venation.In a word, the sick position of primary disease is at the heart, and is in close relations with the five internal organs such as liver,spleen,kidney.Always stagnate because of expectorant foul smell, blockage of the cardiac vessels, conduct not normal, or deficiency of heart-QI, deficiency of both QI and blood, it is unable to beat, arteries and veins gas is not due to the phase continued access.We defend the understanding that theory and irregularly intermittent and regularly intermittent pulse propose the five internal organs deficiency of vital energy, blood vessels do not fill pathomechanism according to battalion, ancestor's's " difficult " " decreasing its heart person; transfer its battalion to defend " purport through 14 difficulties, by the understanding of modern medicine for premature beat, atrial fibrillation, by analysis to various pathogen and pathology of tcm theories, through long-term clinical practice, clearly proposing primary disease and be with motive Yin bivacuity is main pathogenesis, with disturbing the mind in the blood stasis.During in conjunction with atrial fibrillation to the influence of atrium structural remodeling, electric reconstruct, and the formation of complication, observe the intervention effect of Chinese medicine to it, we have declared Liaoning Province education department problem " the centering capsule postpones the influence and the experimentation of depolarization to ventricular muscles " and " the centering capsule is to electricity reconstruct of atrial fibrillation atrium and Ca
2+The influence of-ATP enzyme gene expression ".
Medicine of the present invention is formed:
1. prescription analysis of the present invention:
The present invention is added by zhigancao decoction and simplifies sanction.Cube original idea be the residence harmonizing yingfen and weifen among Replenishing QI and nourishing YIN, the moon that nourishes the five internal organs on the one hand is smart, the change QI of five ZANG-organs fills the five internal organs gas, to help the power of blood fortune; YIN nourishing benefit battalion makes blood vessels full on the other hand.So make blood vessels normal again, ying-qi must be capable, defends and be so incensed that logical, and the mind (comprising the five internal organs) must be supported and cardiopalmus must be put down.
2. the present invention forms the pharmacodynamic study of flavour of a drug:
1) Radix Glycyrrhizae Preparata: effect is the QI invigorating invigorating middle warmer, relieving spasm to stop pain, nourishing the lung to arrest cough, eliminating fire and detoxication, the mediation property of medicine.Sweet in the mouth is flat, returns spleen, stomach, the heart, lung meridian.Gas and property are slow, can rise and can fall." not Lu " " warming the middle warmer and descending qi, stuffy sensation with restlessness is losed heart, and hinders dirty cough, quench the thirst, qualcomm meridian, sharp vim and vigour are separated hundred poison of drug "." medicine origin " " can mend three warmers vigour, coordinating the actions of various ingredients in a prescription is assisted mutually "." book on Chinese herbal medicine converge with ancestor " " strain internal injury, deficiency-weakness of spleen-QI, first YANG deficiency, decline of lung-QI ".Radix Glycyrrhizae Preparata has pair anti-acetylcholine after deliberation, strengthens adrenergic cardiotonic, obviously arrhythmia, antioxidation, antiallergic and anti-aging effects;
2) Radix Rehmanniae: effect is a nourishing YIN and clearing away heat, and removing heat from blood is enriched blood.Sweet in the mouth, hardship are slightly cold, GUIXIN, liver, stomach warp, and thick the falling of matter let out." solar corona " " help heart and gallbladder gas, the peace soul is decided soul, and it is bad to control palpitation with fear labor, and cardiopulmonary decrease ".The Radix Rehmanniae has stronger physiologically active to cardiovascular system, and is bigger to the cardiac function influence.Low dose makes vasoconstriction, and heavy dose distends the blood vessels.The Radix Rehmanniae can obviously resist Levothyroxinnatrium and irritate the inductive rat heart muscle plumpness of stomach, suppresses the heart, brain mitochondria Ca
2+, Mg
2+-atpase activity, thereby protection heart and brain tissues avoid ATP to exhaust and ischemic injuries;
3) Radix Astragali: function is to give birth to usefulness, benefiting QI for strengthening the superficies, inducing diuresis to remove edema.Process usefulness, all weakness of QI syndrome of deficiency of blood are controlled in invigorating the spleen and replenishing QI.Nature and flavor, sweet, tepor is gone into lung, spleen channel." book on Chinese herbal medicine meets the source " " though the property temperature compensation, and can lead to blood circulation regulating, popular meridians are not can hinder in heavily stagnating yet ".Strengthen the function of body fluid and cellular immunization, astragalus root components mainly comprises astragalus polysaccharides, saponin, flavone compound.The single Radix Astragali and compatibility are used can significantly be lowered into fibrocyte collagen synthesis rate, improves connective tissue proliferation and sclerosis of blood vessels, increases blood vessel elasticity, improves amount of blood supply, thereby the arteriosclerosis symptom of senile organism is improved.Effective ingredient in the Radix Astragali can significantly increase myocardial cell membrane calcium pump activity, increases the transhipment of intracellular calcium, thereby reduces too much gathering of the interior calcium ion of myocardial cell.In research, find that Radix Astragali injection can suppress the increase of the L type Calcium Current of virus infected cell, alleviate the influence of virus, and make negative the moving of reversal potential of sodium calcium exchanging electric current sodium calcium exchanging electric current to the myocardial cell of viral infection.And Radix Astragali total glycosides can increase the expression of the mRNA of viral infection myocardial cell sarcoplasmic reticulum calcium pump, and can improve the vigor of sarcoplasmic reticulum calcium pump;
4) Radix Ginseng: can strongly invigorating primordial QI, calm the nerves, impairment caused by overstrain deficient, lack of appetite, the card of all QI and blood seminal fluid deficiencies such as asthenia.Nature and flavor: sweet, little hardship, temperature.Go into spleen, lung meridian." Bencao Jingshu " " Radix Ginseng can be exhausted in hanging down because of yang-energy, and but exogenous pathogen is in a moment.It cures mainly also, tonifying five ZANG-organs then, though kind dirty have five, and explaining in words angry and his like general rule one also, beneficial vital qi, then the five internal organs are all mended ".Radix Ginseng has the effect of protection cardiovascular system, can strengthen myocardial contraction, increases cardiac output, has cardiotonic.While Radix Ginseng energy coronary blood flow increasing, decreased heart rate, function of resisting myocardial ischemia, anti-hypoxia and protection cardiac muscle, the reduction myocardial oxygen consumption, the reduction hemoglobin discharges more oxygen to the affinity of oxygen to tissue.Antifatigue effect to animal is remarkable.Take Radix Ginseng for a long time and can improve the tolerance of rat, quicken the recovery of some variation in stress reflecting nonspecific stimulation;
5) Radix Ophiopogonis: effect is a nourishing YIN and moistening the lung, the stomach reinforcing spermatogenesis, and relieving restlessness clears away heart-fire.Nature and flavor are sweet, little hardship, and cold nature is returned lung, stomach, heart channel." medication heart method " " the reinforcing the heart QI-insufficiency, and control the absurd row of blood ".Radix Ophiopogonis extract can make myocardial ultrastructure indexs such as (change of mitochondrion, nucleus and sarcostyle caryoplasm and the secreted collagens of active proliferation Interstitial cell) significantly improve than model group, the mechanism of action that resists myocardial ischemia Radix Ophiopogonis may with prevent the myocardial cell lipid peroxidation and improve fatty acid metabolism relevant, and present certain dose-effect relationship.Can improve myocardial contraction and cardiac pumping function Radix Ophiopogonis, improves the tolerance of mice ischemic myocardium to hypoxia, improves myocardial cell nutrition, antioxidation, and antifatigue effect promotes humoral immunization, and can alleviate calcium overload;
6) Radix Salviae Miltiorrhizae: blood circulation promoting and blood stasis dispelling, modern pharmacological research confirms: Radix Salviae Miltiorrhizae has blood vessel dilating, microcirculation improvement, reduce whole blood viscosity and plasma viscosity, reduce Angiotensin II, reduce myocardial oxygen consumption, have the atpase activity protective effect, can improve the myocardial ATP enzymatic activity, cardiac muscle is played a protective role;
7) Flos Carthami: the effect of getting its blood circulation promoting and blood stasis dispelling.Modern pharmacological research confirms: Flos Carthami has dilating effect to different parts blood vessels such as heart and brain kidneys, can increase coronary blood flow, have to resist myocardial ischemia, anoxia, suppress the function of platelet adhesion reaction, gathering and release, can improve hemorheological property, reduce blood viscosity;
8) Semen Ziziphi Spinosae: the effect of getting its tranquilizing by nourishing the heart.Modern pharmacological research confirms: Semen Ziziphi Spinosae has arrhythmia and the effect of prevention arrhythmia, and myocardial cell injury is had protective effect.
Beneficial effect of the present invention:
1, the present invention to the deficiency of both QI and YIN, the blood stasis Phlegm-Heat Internal confusion Type cardiopalmus that cause of treatment a variety of causes, breathe hard, have a headache, end when doing when dizzy weak, tiredness with no desire to speak, insomnia and dreamful sleep, lustreless complexion, sensation of oppression and faint pain in the chest, meet labor what for, pareordia discomfort, back part pain, tongue is red partially or indentation, ecchymosis are arranged, thready and weak pulse or knot are for there being obvious curative effects, and the clinical practice effective percentage reaches more than 85%;
2, medicine of the present invention is formed simply, and flavour of a drug are few, and are cheap, are easy to be accepted by the patient.
The specific embodiment:
Embodiment 1:
Radix Glycyrrhizae Preparata 15g, Radix Rehmanniae 20g, Radix Ginseng 15g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 20g.
Embodiment 2:
Radix Glycyrrhizae Preparata 30g, Radix Rehmanniae 20g, Radix Ginseng 15g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
Embodiment 3:
Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 20g, Radix Ginseng 10g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 30g, Flos Carthami 15g, Semen Ziziphi Spinosae 20g.
Embodiment 4:
Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 25g, Radix Ginseng 20g, Radix Astragali 20g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
Embodiment 5:
Radix Glycyrrhizae Preparata 30g, Radix Rehmanniae 25g, Radix Ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
Embodiment 6:
Radix Glycyrrhizae Preparata 40g, Radix Rehmanniae 25g, Radix Ginseng 15g, Radix Astragali 30g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
Embodiment 7:
Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 25g, Radix Ginseng 15g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 25g, Flos Carthami 10g, Semen Ziziphi Spinosae 40g.
Embodiment 8:
Radix Glycyrrhizae Preparata 35g, Radix Rehmanniae 20g, Radix Ginseng 10g, Radix Astragali 25g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 15g, Semen Ziziphi Spinosae 30g.
Embodiment 9:
Radix Glycyrrhizae Preparata 35g, Radix Rehmanniae 30g, Radix Ginseng 20g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 15g, Semen Ziziphi Spinosae 40g.
Animal data:
The present invention postpones the influence and the experimentation of depolarization to ventricular muscles:
Select 85 of healthy SD rats for use, adopt the coronary artery ligation method to set up the Rat of Myocardial Infarction animal model, the male rat of screening ventricular late potential is divided into myocardial infarction model group, verapamil matched group, the heavy dose of group of the present invention, dose,equivalent group of the present invention, average every group of 5 rats at random.Add and do not carry out 5 rats of normal control group that modeling is handled, be five groups altogether.Observe general state of rat and ventricular late potential, QT dispersion and the morphologic variation of myocardial cell of mensuration rat.
Zoopery proves: 1. the present invention of dose,equivalent is not so good as heavy dose of the present invention and verapamil to the ventricular late potential of Rat of Myocardial Infarction, the improvement effect of QT dispersion.2. heavy dose of the present invention has the effect of regulating ventricular late potential, QT dispersion to Rat of Myocardial Infarction, thereby has improved myocardium conduction, has prevented sudden cardiac death.3. heavy dose of the present invention and contrast medicine verapamil are to Rat of Myocardial Infarction ventricular late potential and QT dispersion, and the Ultrastructural improvement degree of ventricular muscles is similar.Illustrate that the present invention has the effect of prevention and treatment to the malignant arrhythmia of myocardial infarction.
The present invention is to electricity reconstruct of atrial fibrillation atrium and Ca
2+The influence of-ATP enzyme gene expression:
Select 100 of healthy male Wistar rats, adopt calcium chloride-acetylcholine mixed liquor to set up the rat animal model of atrial fibrillation in the mode of caudal vein administration.Screening has 30 of the rats of typical atrial fibrillation electrocardiogram performance, is divided into model group, of the present invention group, verapamil group at random, average every group of 10 rats.Add and do not carry out 10 rats of normal control group that modeling is handled, be four groups altogether.Observe the general state of rat, palatelet-selectin, TXB in the observation serum
2, PA I-I, the Ca of cardiac muscular tissue
2+Kinases 2 (EPK2) gene expression is regulated in-ATP, Cx40, L-type calcium channel gene, extracellular, and the morphologic variation of cardiac muscular tissue.
Zoopery proves: 1. the present invention has obvious curative effects to the atrial fibrillation rat model, and symptom of rats and general state all improve significantly and take a turn for the better; 2. the present invention can obviously reduce TXB in the serum of AF rat model
2, PA I-I level, the gene of palatelet-selectin, CX40 and EPK2 expression of gene, thus can reduce platelet activation, obviously improve the preceding state of thrombosis, prevention thrombosis and thromboembolism reduce multiple generation of turning back in the atrium, and the myocardial fibrosis degree is alleviated; 3. the present invention Ca that can obviously raise
2+-ATP enzyme, LTCC expression of gene,, thus calcium overload in the myocardial cell alleviated, delay and corrects atrium electricity reconstruct, stoped the generation of AF and lasting.4. the present invention and Western medicine verapamil hydrochloride relatively can more effective inhibition atrial fibrillation electricity reconstruct (AER) and structural remodelings (ASR), disclosed the mechanism of action and target spot that the present invention treats atrial fibrillation, and atrial fibrillation deficiency of both QI and YIN hold concurrently syndrome of blood stasis and Ca have been described
2+The dependency of-ATP, Cx40, TXB2, PAI-I, L-type calcium channel, EPK2 has confirmed that the present invention can obviously improve clinical efficacy, plays an important role in the treatment of atrial fibrillation.
Clinical data:
The present invention treats unusual 30 examples of ventricular late potential and analyzes:
Selection of clinical 30 routine ventricular late potential positive patients, all to the medicine of treatment premature beat of the present invention, atrial fibrillation, 1 dose of every day, decocting divide 3 times oral, observe patient's clinical symptoms and improve situation.
Clinical research proves: the present invention can obviously improve the clinical efficacy of ventricular late potential positive patient, cures 21 examples after the medication, produce effects 4 examples, and effective 1 example, total effective rate reaches 86.7%.The present invention has the effect of regulating cardiac electrophysiology, promptly by improving myocardial ischemia, regulates the myocardium current potential, stablizes electrocardio-activity, prolongs the ventricular muscles refractory stage to reach, and shortens supranormal period, reaches and improves ventricular muscles conduction, the effect that recovers ventricular late potential.Paper is seen in play-by-play.
The present invention treats the clinical research of deficiency of both QI and YIN ventricular premature contraction:
Selection of clinical 60 routine type of deficiency of both QI and YIN ventricular premature contraction patients, all cases are given the medicine with treatment premature beat of the present invention, atrial fibrillation, the curative effect and the doing well,improving situation of observing Chinese medicine all in the treatment underlying diseases.
Clinical research proves: the present invention can obviously improve ventricular premature contraction patient's clinical efficacy, and the ventricular premature contraction incidence rate obviously reduces after the medication, and has improved patient's quality of life.Paper is seen in play-by-play.
The present invention treats deficiency of both QI and YIN atrial fibrillation 60 routine clinical experiences:
Selection of clinical 60 routine atrial fibrillation patients, all case all in the treatment underlying diseases, is given the medicine with treatment premature beat of the present invention, atrial fibrillation.After the course of treatment, observe the curative effect and the doing well,improving situation of Chinese medicine.
Clinical research proves: the present invention can obviously improve the clinical efficacy of patients with atrial fibrillation, improves patient's quality of life, and total effective rate reaches more than 85%.
Claims (10)
1, a kind of medicine for the treatment of premature beat, atrial fibrillation, comprise Radix Glycyrrhizae Preparata, the Radix Rehmanniae, Radix Ginseng, the Radix Astragali, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Flos Carthami, Semen Ziziphi Spinosae eight flavor Chinese medicines, each constituent content is by weight: Radix Glycyrrhizae Preparata 15-40g, Radix Rehmanniae 20-30g, Radix Ginseng 10-25g, Radix Astragali 20-40g, Radix Ophiopogonis 20-40g, Radix Salviae Miltiorrhizae 20-40g, Flos Carthami 10-25g, Semen Ziziphi Spinosae 20-40g.
2, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 15g, Radix Rehmanniae 20g, Radix Ginseng 15g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 20g.
3, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 30g, Radix Rehmanniae 20g, Radix Ginseng 15g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
4, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 20g, Radix Ginseng 10g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 30g, Flos Carthami 15g, Semen Ziziphi Spinosae 20g.
5, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 25g, Radix Ginseng 20g, Radix Astragali 20g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
6, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 30g, Radix Rehmanniae 25g, Radix Ginseng 20g, Radix Astragali 30g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
7, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 40g, Radix Rehmanniae 25g, Radix Ginseng 15g, Radix Astragali 30g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 10g, Semen Ziziphi Spinosae 25g.
8, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 25g, Radix Rehmanniae 25g, Radix Ginseng 15g, Radix Astragali 20g, Radix Ophiopogonis 20g, Radix Salviae Miltiorrhizae 25g, Flos Carthami 10g, Semen Ziziphi Spinosae 40g.
9, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 35g, Radix Rehmanniae 20g, Radix Ginseng 10g, Radix Astragali 25g, Radix Ophiopogonis 30g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 15g, Semen Ziziphi Spinosae 30g.
10, a kind of medicine for the treatment of premature beat, atrial fibrillation according to claim 1 is characterized in that the weight ratio of each constituent content is: Radix Glycyrrhizae Preparata 35g, Radix Rehmanniae 30g, Radix Ginseng 20g, Radix Astragali 25g, Radix Ophiopogonis 25g, Radix Salviae Miltiorrhizae 20g, Flos Carthami 15g, Semen Ziziphi Spinosae 40g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101577552A CN101422562A (en) | 2007-10-29 | 2007-10-29 | Medicine for treating premature beat and atrial fibrillation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101577552A CN101422562A (en) | 2007-10-29 | 2007-10-29 | Medicine for treating premature beat and atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101422562A true CN101422562A (en) | 2009-05-06 |
Family
ID=40613593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101577552A Pending CN101422562A (en) | 2007-10-29 | 2007-10-29 | Medicine for treating premature beat and atrial fibrillation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101422562A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574450B (en) * | 2009-06-15 | 2012-05-02 | 李成国 | Drug for treating heart disease and preparation method thereof |
| CN102805839A (en) * | 2012-08-01 | 2012-12-05 | 赵庆军 | Method for preparing traditional Chinese medicine for treating insomnia caused by precordial pain |
| CN104547522A (en) * | 2014-12-26 | 2015-04-29 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating arrhythmia and application of traditional Chinese medicine composition |
| CN108478703A (en) * | 2018-06-27 | 2018-09-04 | 辽宁中医药大学 | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis |
| CN113476526A (en) * | 2021-08-12 | 2021-10-08 | 江苏省中医药研究院 | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method |
| CN115177691A (en) * | 2022-07-18 | 2022-10-14 | 河南中医药大学第一附属医院 | Traditional Chinese medicine composition for treating ventricular premature beat and application thereof |
-
2007
- 2007-10-29 CN CNA2007101577552A patent/CN101422562A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101574450B (en) * | 2009-06-15 | 2012-05-02 | 李成国 | Drug for treating heart disease and preparation method thereof |
| CN102805839A (en) * | 2012-08-01 | 2012-12-05 | 赵庆军 | Method for preparing traditional Chinese medicine for treating insomnia caused by precordial pain |
| CN104547522A (en) * | 2014-12-26 | 2015-04-29 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating arrhythmia and application of traditional Chinese medicine composition |
| CN104547522B (en) * | 2014-12-26 | 2017-11-28 | 上海中医药大学附属岳阳中西医结合医院 | A kind of Chinese medicine composition for treating arrhythmia cordis and its application |
| CN108478703A (en) * | 2018-06-27 | 2018-09-04 | 辽宁中医药大学 | A kind of Chinese medicine composition and quality determining method for treating arrhythmia cordis |
| CN113476526A (en) * | 2021-08-12 | 2021-10-08 | 江苏省中医药研究院 | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method |
| CN115177691A (en) * | 2022-07-18 | 2022-10-14 | 河南中医药大学第一附属医院 | Traditional Chinese medicine composition for treating ventricular premature beat and application thereof |
| CN115177691B (en) * | 2022-07-18 | 2023-06-06 | 河南中医药大学第一附属医院 | Traditional Chinese medicine composition for treating ventricular premature beat and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101991816B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN1383846A (en) | Heart-strengthening and blood circulation-promoting liquid medicine for treating heart diseases | |
| CN101422562A (en) | Medicine for treating premature beat and atrial fibrillation | |
| CN105561214A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN103202879B (en) | Traditional Chinese medicine composition for treating chronic cardiac failure and preparation method thereof | |
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN101332231A (en) | Medicine for treating heart failure | |
| CN103610936B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of coronary heart disease | |
| CN102048939B (en) | Medicament for treating sinus bradycardia | |
| CN101361797B (en) | Traditional Chinese medicine pressure-reduction insoles | |
| CN101342207B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN100382834C (en) | Traditional Chinese medicine for treating coronary heart disease and angina pectoris | |
| CN103041327A (en) | Traditional Chinese medicine for treating sick sinus syndrome single nucleotide and preparation method thereof | |
| CN102343049A (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN100558387C (en) | The Chinese medicinal capsule of treatment heart failure | |
| CN103638428A (en) | Traditional Chinese medicinal composition for treating coronary heart disease | |
| CN104383443A (en) | Traditional Chinese medicine composition for treating arrhythmia | |
| CN104117020A (en) | Traditional Chinese medicinal formula for treating atrial fibrillation | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN102961561A (en) | Chinese medicinal composition for treating coronary heart disease | |
| CN101229314B (en) | Chinese traditional medicine preparation for treating myocardial infarction induced by myocardial ischemia | |
| CN102743578B (en) | Traditional Chinese medicine preparation for promoting blood circulation to remove meridian obstruction | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN104524313A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090506 |